These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37506604)

  • 1. Neurophysiological correlates of non-motor symptoms in late premanifest and early-stage manifest huntington's disease.
    Davis MC; Hill AT; Fitzgerald PB; Bailey NW; Stout JC; Hoy KE
    Clin Neurophysiol; 2023 Sep; 153():166-176. PubMed ID: 37506604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of medial prefrontal transcranial alternating current stimulation on neural activity and connectivity in people with Huntington's disease and neurotypical controls.
    Davis MC; Fitzgerald PB; Bailey NW; Sullivan C; Stout JC; Hill AT; Hoy KE
    Brain Res; 2023 Jul; 1811():148379. PubMed ID: 37121424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EEG Functional Connectivity and Cognitive Variables in Premanifest and Manifest Huntington's Disease: EEG Low-Resolution Brain Electromagnetic Tomography (LORETA) Study.
    Delussi M; Nazzaro V; Ricci K; de Tommaso M
    Front Physiol; 2020; 11():612325. PubMed ID: 33391027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Changes in Functional Connectivity of Striatum-Prefrontal and Striatum-Motor Circuits in Premanifest Huntington's Disease.
    Kronenbuerger M; Hua J; Bang JYA; Ultz KE; Miao X; Zhang X; Pekar JJ; van Zijl PCM; Duan W; Margolis RL; Ross CA
    Neurodegener Dis; 2019; 19(2):78-87. PubMed ID: 31412344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.
    Tabrizi SJ; Reilmann R; Roos RA; Durr A; Leavitt B; Owen G; Jones R; Johnson H; Craufurd D; Hicks SL; Kennard C; Landwehrmeyer B; Stout JC; Borowsky B; Scahill RI; Frost C; Langbehn DR;
    Lancet Neurol; 2012 Jan; 11(1):42-53. PubMed ID: 22137354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative Electroencephalographic Analysis Provides an Early-Stage Indicator of Disease Onset and Progression in the zQ175 Knock-In Mouse Model of Huntington's Disease.
    Fisher SP; Schwartz MD; Wurts-Black S; Thomas AM; Chen TM; Miller MA; Palmerston JB; Kilduff TS; Morairty SR
    Sleep; 2016 Feb; 39(2):379-91. PubMed ID: 26446107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Motivationally salient cue processing measured using the monetary incentive delay (MID) task with electroencephalography (EEG): A potential marker of apathy in Huntington's disease.
    Davis MC; Hill AT; Fitzgerald PB; Stout JC; Hoy KE
    Neuropsychologia; 2022 Dec; 177():108426. PubMed ID: 36414099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's Disease.
    Martinez-Horta S; Perez-Perez J; van Duijn E; Fernandez-Bobadilla R; Carceller M; Pagonabarraga J; Pascual-Sedano B; Campolongo A; Ruiz-Idiago J; Sampedro F; Landwehrmeyer GB; ; Kulisevsky J
    Parkinsonism Relat Disord; 2016 Apr; 25():58-64. PubMed ID: 26898966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EEG low-resolution brain electromagnetic tomography (LORETA) in Huntington's disease.
    Painold A; Anderer P; Holl AK; Letmaier M; Saletu-Zyhlarz GM; Saletu B; Bonelli RM
    J Neurol; 2011 May; 258(5):840-54. PubMed ID: 21161261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apathy predicts rate of cognitive decline over 24 months in premanifest Huntington's disease.
    Andrews SC; Langbehn DR; Craufurd D; Durr A; Leavitt BR; Roos RA; Tabrizi SJ; Stout JC;
    Psychol Med; 2021 Jun; 51(8):1338-1344. PubMed ID: 32063235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal resting state fMRI analysis in healthy controls and premanifest Huntington's disease gene carriers: a three-year follow-up study.
    Odish OF; van den Berg-Huysmans AA; van den Bogaard SJ; Dumas EM; Hart EP; Rombouts SA; van der Grond J; Roos RA;
    Hum Brain Mapp; 2015 Jan; 36(1):110-9. PubMed ID: 25139578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired face-like object recognition in premanifest Huntington's disease.
    Martínez-Horta S; Horta-Barba A; Perez-Perez J; Antoran M; Pagonabarraga J; Sampedro F; Kulisevsky J
    Cortex; 2020 Feb; 123():162-172. PubMed ID: 31794910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormal Electrophysiological Motor Responses in Huntington's Disease: Evidence of Premanifest Compensation.
    Turner LM; Croft RJ; Churchyard A; Looi JC; Apthorp D; Georgiou-Karistianis N
    PLoS One; 2015; 10(9):e0138563. PubMed ID: 26406226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of Working Capacity Changes Related to Huntington's Disease: A Longitudinal Study.
    van der Zwaan KF; Jacobs M; van Zwet EW; Roos RAC; de Bot ST
    J Huntingtons Dis; 2021; 10(2):269-276. PubMed ID: 33523014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.
    Tabrizi SJ; Scahill RI; Owen G; Durr A; Leavitt BR; Roos RA; Borowsky B; Landwehrmeyer B; Frost C; Johnson H; Craufurd D; Reilmann R; Stout JC; Langbehn DR;
    Lancet Neurol; 2013 Jul; 12(7):637-49. PubMed ID: 23664844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basal ganglia-cortical structural connectivity in Huntington's disease.
    Novak MJ; Seunarine KK; Gibbard CR; McColgan P; Draganski B; Friston K; Clark CA; Tabrizi SJ
    Hum Brain Mapp; 2015 May; 36(5):1728-40. PubMed ID: 25640796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognition in Huntington's disease in manifest, premanifest and converting gene carriers over ten years.
    Hart EP; Dumas EM; Giltay EJ; Middelkoop HA; Roos RA
    J Huntingtons Dis; 2013; 2(2):137-47. PubMed ID: 25063511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.
    Tabrizi SJ; Langbehn DR; Leavitt BR; Roos RA; Durr A; Craufurd D; Kennard C; Hicks SL; Fox NC; Scahill RI; Borowsky B; Tobin AJ; Rosas HD; Johnson H; Reilmann R; Landwehrmeyer B; Stout JC;
    Lancet Neurol; 2009 Sep; 8(9):791-801. PubMed ID: 19646924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha-theta border EEG abnormalities in preclinical Huntington's disease.
    Ponomareva N; Klyushnikov S; Abramycheva N; Malina D; Scheglova N; Fokin V; Ivanova-Smolenskaia I; Illarioshkin S
    J Neurol Sci; 2014 Sep; 344(1-2):114-20. PubMed ID: 25015843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Executive impairment is associated with unawareness of neuropsychiatric symptoms in premanifest and early Huntington's disease.
    Andrews SC; Craufurd D; Durr A; Leavitt BR; Roos RA; Tabrizi SJ; Stout JC
    Neuropsychology; 2018 Nov; 32(8):958-965. PubMed ID: 30211612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.